Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.55 |
| ▸ | VNN1 | O95497 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22087745 | 1.00 | USP30 (0.58) | USP30GPR119VNN1JAK2JAK1 | |
| SCHEMBL21790196 | 0.88 | VNN1 (0.51) | USP30GPR119VNN1JAK2JAK1 | |
| SCHEMBL10223191 | 0.88 | USP30 (0.53) | USP30GPR119VNN1JAK2JAK1 | |
| SCHEMBL28834232 | 0.82 | USP30 (0.52) | USP30GPR119VNN1JAK2JAK1 | |
| SCHEMBL28834231 | 0.82 | USP30 (0.52) | USP30GPR119VNN1JAK2JAK1 | |
| SCHEMBL13326823 | 0.82 | GPR119 (0.53) | USP30GPR119JAK2JAK1 | |
| SCHEMBL972277 | 0.82 | GPR119 (0.53) | USP30GPR119JAK2JAK1 | |
| SCHEMBL1307415 | 0.81 | GPR119 (0.60) | USP30GPR119MEN1KMT2A | |
| SCHEMBL29862618 | 0.81 | USP30 (0.48) | USP30GPR119VNN1JAK2JAK1 | |
| SCHEMBL28834263 | 0.81 | USP30 (0.48) | USP30GPR119VNN1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| US-20220048885-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-02-17 | — | — | US | disclosed |
| US-11078182-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-03 | — | — | US | disclosed |
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-04 | — | — | US | disclosed |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-15 | — | — | US | disclosed |
| WO-2020114943-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020114947-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
| US-20200172508-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-04 | — | — | US | disclosed |
| WO-2020043658-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-05 | — | — | WO | disclosed |
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | USP30 3167/4885GPR119 2006/4885VNN1 23/4885 |
| US-20220048885-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | USP30 3167/4885GPR119 2006/4885VNN1 23/4885 |
| US-20200172508-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | USP30 3167/4885GPR119 2006/4885VNN1 23/4885 |
| US-11078182-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | USP30 3167/4885GPR119 2006/4885VNN1 23/4885 |
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | USP30 3167/4885GPR119 2006/4885VNN1 23/4885 |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | USP30 3167/4885GPR119 2006/4885VNN1 23/4885 |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | USP30 3167/4885GPR119 2006/4885VNN1 23/4885 |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | USP30 3167/4885GPR119 2006/4885VNN1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.